trending Market Intelligence /marketintelligence/en/news-insights/trending/ERkPYmcav__tGHYbNHuGCg2 content esgSubNav
In This List

FSD Pharma to undertake 1-for-201 share consolidation, appoints director

Video

S&P Capital IQ Pro | Powering Your Edge

Video

S&P Capital IQ Pro | Unrivaled Sector Coverage

Blog

Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud

Blog

Investment Research Analysts Providing Greater Coverage on Inflation


FSD Pharma to undertake 1-for-201 share consolidation, appoints director

FSD Pharma Inc. is consolidating its class A multiple voting shares and its class B subordinate voting shares, each on a 1-to-201 basis.

Following consolidation, there will be 72 issued and outstanding class A shares, representing 276,660 votes or about 72% of FSD's voting rights.

Cobourg, Ontario-based FSD expects to commence trading the class B shares on the Canadian Securities Exchange on a post-consolidation basis under its existing name and ticker symbol starting Oct. 16, with a record date of Oct. 17.

The consolidation will reduce the number of FSD's issued and outstanding class B shares to about 7,874,809 from 1,582,966,252. This will allow the company to list class B shares on a major U.S. exchange.

Following the consolidation, the company will have about 1,033,782 stock options and warrants to purchase 576,499 class B shares outstanding.

Additionally, FSD said it appointed Stephen Buyer, a former U.S. representative from Indiana, to its board.